Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA -Mutated Relapsed Epithelial Ovarian Cancer: A Case Report.

Bing Qian, Wenshu Leng,Zhengqing Yan,Jin Lu,Shiqing Chen,Huan Yi,Zhi Jiang

Frontiers in oncology（2022）

引用 4|浏览1

暂无评分

摘要

This case highlighted that OC patients harboring pathogenic gene alterations in the homologous recombination pathway might achieve clinical benefit from PARP inhibitors, which should be confirmed in further studies.

查看译文

关键词

FANCA,PARP inhibitor,clinical benefit,germline,ovarian cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要